NasdaqGM - Nasdaq Real Time Price • USD
Zai Lab Limited (ZLAB)
As of 9:50 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 10 | 9 |
| Avg. Estimate | -0.92 | -0.88 | -2.4 | -0.76 |
| Low Estimate | -1.09 | -1.06 | -3.87 | -2.63 |
| High Estimate | -0.75 | -0.75 | 5.6 | 3.4 |
| Year Ago EPS | -0.51 | -1.25 | -3.5 | -2.4 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 10 | 9 |
| Avg. Estimate | 75.24M | 85.46M | 382.89M | 623.82M |
| Low Estimate | 73M | 82M | 374.24M | 539.71M |
| High Estimate | 77.66M | 87.1M | 398M | 871M |
| Year Ago Sales | 64.97M | 70.65M | 266.72M | 382.89M |
| Sales Growth (year/est) | 15.80% | 21.00% | 43.60% | 62.90% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.95 | -0.79 | -1.04 | -0.86 |
| EPS Actual | -0.51 | -1.25 | -0.71 | -1 |
| Difference | 0.44 | -0.46 | 0.33 | -0.14 |
| Surprise % | 46.30% | -58.20% | 31.70% | -16.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.92 | -0.88 | -2.4 | -0.76 |
| 7 Days Ago | -0.93 | -0.88 | -2.4 | -0.75 |
| 30 Days Ago | -0.9 | -0.85 | -2.24 | -1.26 |
| 60 Days Ago | -0.77 | -0.72 | -3 | -1.11 |
| 90 Days Ago | -0.77 | -0.72 | -2.93 | -1.11 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 1 | -- |
| Up Last 30 Days | 1 | -- | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | 1 | -- | 1 |
Growth Estimates
| CURRENCY IN USD | ZLAB | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -80.40% | -- | -- | 1.50% |
| Next Qtr. | 29.60% | -- | -- | 12.10% |
| Current Year | 31.40% | -- | -- | 4.40% |
| Next Year | 68.30% | -- | -- | 13.20% |
| Next 5 Years (per annum) | -77.40% | -- | -- | 10.97% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Citigroup: Buy to Buy | 2/29/2024 |
| Initiated | Morgan Stanley: Overweight | 12/14/2023 |
| Maintains | JP Morgan: Overweight to Overweight | 11/30/2023 |
| Maintains | Citigroup: Buy to Buy | 10/26/2023 |
| Maintains | Goldman Sachs: Buy to Buy | 10/26/2023 |
| Maintains | JP Morgan: Overweight to Overweight | 10/17/2023 |
Related Tickers
BGNE BeiGene, Ltd.
151.60
+2.05%
RCUS Arcus Biosciences, Inc.
14.77
+0.27%
DNLI Denali Therapeutics Inc.
15.22
+1.74%
IGMS IGM Biosciences, Inc.
7.54
-1.44%
IMAB I-Mab
1.8202
+0.56%
LEGN Legend Biotech Corporation
44.72
+0.68%
SNDX Syndax Pharmaceuticals, Inc.
20.72
+0.73%
AKRO Akero Therapeutics, Inc.
19.23
+1.58%
ALNY Alnylam Pharmaceuticals, Inc.
144.46
+0.52%
VRNA Verona Pharma plc
15.27
-0.26%